Advances in Host-Directed Therapies Against Tuberculosis

Section 1: Introduction

Chapter 1:           Introduction: An overview of host-directed therapies for tuberculosisDaniel Frank, Robert Mahon



 

Section 2: Targeting immunometabolism

Chapter 2:           Sirtuin deacetylases: Linking Mycobacterial infection and host metabolism

Lorissa Smulan, Hardy Kornfeld, and Amit Singhal

Chapter 3:           The mammalian target of rapamycin complex 1 (mTORC1): an ally of M. tuberculosis in host cells

Natalie Bruiners, Valentina Guerrini, Maria Laura Gennaro

Chapter 4:           HIF-1 as a potential therapeutic target for tuberculosis treatment

                                Qingkui Jiang, Maria Laura Gennaro, Lanbo Shi

Chapter 5:           Nuclear receptors in host-directed therapies against tuberculosis

                                Eun-Kyeong Jo

 

Section 3: Enhancing anti-mycobacterial mechanisms

Chapter 6:           Autophagy as a target for host-directed therapy against tuberculosis

                                Surbhi Verma, Raman Deep

Petros C. Karakousis, M.D., is an infectious diseases-trained physician scientist and Professor of Medicine at the Johns Hopkins University School of Medicine. His research focus is on host-pathogen interactions contributing to Mycobacterium tuberculosis persistence and antibiotic tolerance. His laboratory is actively investigating the repurposing of clinically available agents with immune-modulatory properties as adjunctive host-directed therapy, in order to shorten the duration of TB treatment and improve lung pathology.

Maria Laura Gennaro, M.D., is Professor of Medicine at Rutgers New Jersey School of Medicine. Her laboratory studies mechanisms of adaptation expressed by Mycobacterium tuberculosis and by the host macrophage during infection, with the goal of finding targets for therapeutic intervention. She has a specific interest in macrophage lipid metabolism, which is altered following M. tuberculosis infection, thereby promoting bacterial survival.

Richard Hafner, M.D., is an infectious diseases-trained physician and Chief of the TB Clinical Research Branch in the Division of AIDS at NIAID/NIH. Throughout his career, he has had a long-standing interest in advancing innovative host-directed therapies for infections. He has been involved in several clinical trials, authored various articles, and hosted multiple scientific meetings related to research to develop targeted HDTs for TB.